Ogalvibart
Based on 1 Customer Validation
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.02%
- CAS. Nr.: 2599039-60-6
- Molecular Weight:145.06 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
SARS-CoV-2
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rhesus macaques (3-11 years old)[1].
-
Dosage:10 mg/kg (in combination with 10 mg/kg C144LS)
-
Administration:75 days before infection
-
Result:Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
YP_009724390.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SARS-CoV-2 S Protein RBD (HEK293, Fc, HY-P73397) can bind Ogalvibart. The EC50 for this effect is 5.194 ng/mL.
Chemical Information
-
CAS. Nr. 2599039-60-6
-
Appearance Liquid
-
Molecular Weight 145.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Ogalvibart]
-
Synonyms
C-135-LS; BMS-986414
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)